The price of Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) shares last traded on Wall Street rose 1.75% to $12.81.
Based on available information, 5 analysts follow Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $25.00 and a low of $15.00, we find $24.00. Given the previous closing price of $12.59, this indicates a potential upside of 90.63 percent. CPRX stock price is now -3.54% away from the 50-day moving average and -15.92% away from the 200-day moving average. The market capitalization of the company currently stands at $1.36B.
Among analysts, 1 rate the stock a hold while 4 rate it a buy. Brokers who have rated the stock have averaged $22.40 as their price target over the next twelve months.
With the price target enhanced from $10 to $15.50, ROTH Capital Downgraded its rating from Buy to Neutral for Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX).
In other news, MCENANY PATRICK J, President and CEO sold 26,151 shares of the company’s stock on May 15. The stock was sold for $345,978 at an average price of $13.23. Upon completion of the transaction, the President and CEO now directly owns 3,945,436 shares in the company, valued at $50.54 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 05, Director Tierney David S sold 30,000 shares of the business’s stock. A total of $504,900 was realized by selling the stock at an average price of $16.83. This leaves the insider owning 313,541 shares of the company worth $4.02 million. Insiders disposed of 3,710,383 shares of company stock worth roughly $47.53 million over the past 1 year. A total of 5.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CPRX stock. A new stake in Catalyst Pharmaceuticals Inc. shares was purchased by PACER ADVISORS, INC. during the first quarter worth $6,581,000. NORGES BANK invested $4,027,000 in shares of CPRX during the first quarter. In the first quarter, SCHRODER INVESTMENT MANAGEMENT GROUP acquired a new stake in Catalyst Pharmaceuticals Inc. valued at approximately $3,555,000. PARADIEM, LLC acquired a new stake in CPRX for approximately $3,031,000. MOODY ALDRICH PARTNERS LLC purchased a new stake in CPRX valued at around $2,589,000 in the second quarter. In total, there are 362 active investors with 83.20% ownership of the company’s stock.
A candlestick chart of Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) showed a price of $12.60 on Tuesday morning. During the past 12 months, Catalyst Pharmaceuticals Inc. has had a low of $7.36 and a high of $22.11. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.50, and a quick ratio of 3.30. The fifty day moving average price for CPRX is $13.22 and a two-hundred day moving average price translates $15.24 for the stock.
The latest earnings results from Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at $0.41, beating analysts’ expectations of $0.32 by 0.09. This compares to $0.12 EPS in the same period last year. The net profit margin was 38.80% and return on equity was 34.70% for CPRX. The company reported revenue of $85.37 million for the quarter, compared to $43.09 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 98.12 percent. For the current quarter, analysts expect CPRX to generate $92.46M in revenue.
Catalyst Pharmaceuticals Inc.(CPRX) Company Profile
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
